S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
NASDAQ:OPGN

OpGen (OPGN) Stock Price, News & Analysis

$0.71
+0.01 (+1.43%)
(As of 04/11/2024 ET)
Today's Range
$0.67
$0.75
50-Day Range
$0.32
$0.78
52-Week Range
$0.17
$3.84
Volume
326,061 shs
Average Volume
4.94 million shs
Market Capitalization
$7.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

OpGen MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
22.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of OpGen in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.02) to ($0.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.29 out of 5 stars

OPGN stock logo

About OpGen Stock (NASDAQ:OPGN)

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

OPGN Stock Price History

OPGN Stock News Headlines

Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Dow Gains 100 Points; McCormick Posts Upbeat Results
Nasdaq Gains Over 50 Points; US Durable Goods Orders Rise In February
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
OpGen Investor David Lazar Is Named CEO
Opgen Inc
OpGen Inc OPGN
OpGen surges after announcing private placement
OpGen, Inc. (OPGN) interactive stock chart – Yahoo Finance
Why Is OpGen (OPGN) Stock Up 540% Today?
See More Headlines
Receive OPGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2023
Today
4/12/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:OPGN
Employees
85
Year Founded
N/A

Profitability

Net Income
$-37,280,000.00
Net Margins
-852.18%
Pretax Margin
-852.18%

Debt

Sales & Book Value

Annual Sales
$3.07 million
Book Value
$2.61 per share

Miscellaneous

Free Float
9,881,000
Market Cap
$7.11 million
Optionable
Not Optionable
Beta
-0.71
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives


OPGN Stock Analysis - Frequently Asked Questions

Should I buy or sell OpGen stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OPGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPGN, but not buy additional shares or sell existing shares.
View OPGN analyst ratings
or view top-rated stocks.

How have OPGN shares performed in 2024?

OpGen's stock was trading at $0.42 on January 1st, 2024. Since then, OPGN stock has increased by 69.1% and is now trading at $0.7101.
View the best growth stocks for 2024 here
.

Are investors shorting OpGen?

OpGen saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,230,000 shares, an increase of 10,621.2% from the March 15th total of 20,800 shares. Based on an average daily trading volume, of 1,670,000 shares, the days-to-cover ratio is currently 1.3 days. Approximately 22.4% of the shares of the company are short sold.
View OpGen's Short Interest
.

When is OpGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our OPGN earnings forecast
.

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) released its earnings results on Thursday, August, 10th. The medical research company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by $0.22. The medical research company had revenue of $0.74 million for the quarter, compared to analysts' expectations of $0.90 million. OpGen had a negative trailing twelve-month return on equity of 316.30% and a negative net margin of 852.18%. During the same period last year, the business earned ($2.60) EPS.

When did OpGen's stock split?

OpGen's stock reverse split on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of OpGen own?
When did OpGen IPO?

OpGen (OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

How do I buy shares of OpGen?

Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPGN) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners